Haemonetics Corp (HAE) 36.66 $HAE
Post Earnings Update: Haemonetics Has Climbed 6.9% Higher in Past 2 Weeks (HAE)
Comtex SmarTrend(R) - Mon Nov 17, 8:53AM CST
When Haemonetics (NYSE:HAE) reported earnings 14 days ago on November 3rd, 2014, analysts, on average, expected the company to report earnings of $0.45 on sales of $230.0 million. The company actually reported EPS of $0.47 on sales of $227.6 million, beating EPS estimates by $0.02 and missing revenue estimates by $2.4 million. Shares of Haemonetics have climbed from $34.74 to $37.13, representing a gain of 6.9% since the company reported earnings 14 days ago.
HAE: 36.66 (-0.33)
Haemonetics to Present at the Jefferies 2014 Global Healthcare Conference
PR Newswire - Tue Nov 11, 3:00PM CST
Haemonetics Corporation (NYSE: HAE) announced today that Gerry Gould, Vice President, Investor Relations, will present at the Jefferies 2014 Global Healthcare Conference in London, England on November 20, 2014 at 8:40 am GMT.
HAE: 36.66 (-0.33)
Update: Haemonetics Needs A Sales Growth Infusion Following Q3 Sales Miss And EPS Beat
Martin Vlcek - at Seeking Alpha - Wed Nov 05, 8:56AM CST
HAE: 36.66 (-0.33)
NYSE stocks posting largest percentage decreases
AP - Tue Nov 04, 5:02PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on New York Stock Exchange at the close of trading:
TLM.TO: 5.04 (+0.78), HLF: 38.79 (-1.92), FRM: 7.34 (-0.13), TLM: 4.29 (+0.60), AKS: 5.20 (-0.13), CIE: 7.82 (+0.19), RCAP: 11.81 (-0.10), GDP: 3.93 (-0.33), LRE: 7.47 (-0.06), HAE: 36.66 (-0.33), S: 4.08 (-0.32), SGY: 13.64 (+0.08), BAS: 5.22 (+0.05), GVA: 35.74 (-0.48), HELI: 3.62 (-0.04), AP: 17.67 (-0.27), CRK: 5.26 (-0.49)
Haemonetics Q2 Earnings Beat Estimates but Decline Y/Y - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 12:20PM CST
Haemonetics Corporation (HAE) reported adjusted earnings of 47 cents per share in the second quarter of fiscal 2015.
BSX: 13.00 (+0.11), ICUI: 80.95 (-1.04), ABAX: 57.20 (+0.61), HAE: 36.66 (-0.33)
Haemonetics' (HAE) CEO Brian Concannon on Q2 2015 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Mon Nov 03, 10:42AM CST
HAE: 36.66 (-0.33)
Haemonetics affirms revenue and earnings guidance after FQ2 results
Seeking Alpha - at Seeking Alpha - Mon Nov 03, 6:54AM CST
HAE: 36.66 (-0.33)
Haemonetics beats 2Q profit forecasts
Automated Insights - Mon Nov 03, 5:18AM CST
BRAINTREE, Mass. (AP) _ Haemonetics Corp. (HAE) on Monday reported fiscal second-quarter earnings of $7.5 million.
HAE: 36.66 (-0.33)
Haemonetics beats by $0.01, misses on revenue
Seeking Alpha - at Seeking Alpha - Mon Nov 03, 5:02AM CST
HAE: 36.66 (-0.33)
Haemonetics Reports 2nd Quarter Fiscal 2015 Revenue of $228 Million and Adjusted EPS of $0.47; Reaffirms Revenue and Earnings Guidance
PR Newswire - Mon Nov 03, 5:00AM CST
Haemonetics Corporation (NYSE: HAE) today reported second quarter fiscal 2015 revenue of $227.6 million, down 3.5%. In constant currency, revenue declined 2.6% in the quarter. The Company reported second quarter GAAP net income of $7.5 million and GAAP net income per share of $0.14. Exclusive of transformation, restructuring and deal amortization expenses detailed below, adjusted net income was $24.3 million and adjusted earnings per share were $0.47, both down 29%.[1]
HAE: 36.66 (-0.33)
Notable earnings before Monday’s open
Seeking Alpha - at Seeking Alpha - Sun Nov 02, 4:30PM CST
ACW: 4.57 (-0.14), SYY: 39.33 (-0.80), L: 39.44 (-0.98), EEP: 38.31 (-0.94), SNH: 22.60 (+0.08), INN: 11.71 (-0.28), ITG: 19.60 (-0.21), NSP: 31.36 (-0.48), S: 4.08 (-0.32), ALE: 52.12 (-0.43), GVA: 35.74 (-0.48), MCY: 54.42 (-1.00), ARNA: 3.91 (-0.18), CHD: 76.00 (-0.80), ARE: 87.94 (-1.21), USAK: 22.52 (-0.24), BWP: 15.81 (+0.07), KRG: 27.78 (unch), CYOU: 23.01 (+0.40), MNKD: 5.11 (-0.14), HNT: 51.50 (-0.11), AMH: 16.89 (-0.22), ARCB: 44.00 (+0.21), ANIP: 54.28 (+2.33), AMG: 194.80 (-9.02), HAE: 36.66 (-0.33), SOHU: 47.82 (+0.37), CNA: 37.79 (-0.72)
Haemonetics reports November 3
Seeking Alpha - at Seeking Alpha - Sat Nov 01, 4:46PM CDT
HAE: 36.66 (-0.33)
Is Haemonetics (HAE) Poised to Beat on Q2 Earnings? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Oct 30, 5:15PM CDT
Haemonetics (HAE) has delivered positive earnings surprises in three of the past four quarters with an average beat of 1.9%
HAE: 36.66 (-0.33), HTWR: 70.66 (+0.18), HOLX: 25.85 (-0.52), HSP: 60.33 (-1.75)
3PEA International and Haemonetics Partner to Integrate PaySign Connect with Haemonetics' Donor Management System
Business Wire - Tue Oct 21, 7:49AM CDT
3PEA International, Inc. (OTCBB:TPNL)(OTCQB:TPNL), a vertically integrated provider of innovative prepaid card programs and processing services for corporate, consumer and government applications, today announced that 3PEA and Haemonetics Corporation (NYSE:HAE) have entered into an agreement whereby 3PEA International will integrate its PaySign(R) Connect prepaid debit card solution with Haemonetics' Donor Management System ("DMS"
. The integration will allow users of the Haemonetics DMS to use the PaySign Connect payment solution for the plasma industry. This partnership will bring together the best of both worlds, the industry leading Haemonetics Donor Management System and 3PEA's PaySign(R) Connect, an intuitive, easy-to-use, fully tokenized payment system tailored to the unique requirements of the plasma collection industry.
HAE: 36.66 (-0.33)
Haemonetics Sets Date for Second Quarter Fiscal Year 2015 Earnings Release: November 3, 2014
PR Newswire - Mon Oct 06, 3:00PM CDT
Haemonetics Corporation (NYSE:HAE) will announce its earnings for the second quarter of its fiscal year 2015 on November 3, 2014 in a pre-market press release. The Company will host a webcast to discuss and answer questions about the press release at 8:00 am eastern time on November 3, 2014.
HAE: 36.66 (-0.33)
Perrigo Sells Some Assets to Imago Pharmaceuticals - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 03, 3:45PM CDT
Perrigo (PRGO) has out licensed some of its early-stage assets.
BIIB: 344.49 (+2.16), PRGO: 153.41 (-3.13), ABAX: 57.20 (+0.61), HAE: 36.66 (-0.33)
Walgreens Earnings in Line, Alliance Boots Shows Synergy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 30, 9:45AM CDT
Walgreen Co. (WAG) reported adjusted net earnings of 74 cents per share in the fourth quarter of fiscal 2014.
ABAX: 57.20 (+0.61), HAE: 36.66 (-0.33), CVS: 89.94 (-0.99), WAG: 74.50 (+1.49)
Data Intensity Fortifies Track Record of Success in Oracle EBS R12 Implementations and Upgrades
PR Newswire - Tue Sep 23, 8:30AM CDT
Data Intensity, the industry leader in managed and cloud services for Oracle technologies and applications, today announced a significant milestone in the company's rich history of driving implementations and upgrades to Oracle E-Business Suite (EBS) Release 12 (R12) for its global customers. Data Intensity is celebrating the inception of its dedicated application engineering team, established five years ago this month to address the market need for expertise in planning, managing and executing on the most complex Oracle projects. The team also recently completed one of its most challenging upgrades to date for Haemonetics Corp, a global healthcare company that provides innovative blood management solutions. This deployment was one of ten R12 projects Data Intensity has delivered successfully this year, and the most recent of the 70+ R12-focused engagements the team has completed since the technology's release in 2007.
HAE: 36.66 (-0.33)
Haemonetics (HAE) Poised on Strong Q2, Optimistic Outlook - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Sep 19, 5:00PM CDT
On Sep 19, 2014, we issued an updated research report on Haemonetics Corporation (HAE).
ICUI: 80.95 (-1.04), ABAX: 57.20 (+0.61), HAE: 36.66 (-0.33), HSP: 60.33 (-1.75)
Post Earnings Update: Haemonetics Has Climbed 6.9% Higher in Past 2 Weeks (HAE)
Comtex SmarTrend(R) - Mon Nov 17, 8:53AM CST
When Haemonetics (NYSE:HAE) reported earnings 14 days ago on November 3rd, 2014, analysts, on average, expected the company to report earnings of $0.45 on sales of $230.0 million. The company actually reported EPS of $0.47 on sales of $227.6 million, beating EPS estimates by $0.02 and missing revenue estimates by $2.4 million. Shares of Haemonetics have climbed from $34.74 to $37.13, representing a gain of 6.9% since the company reported earnings 14 days ago.
HAE: 36.66 (-0.33)
Haemonetics to Present at the Jefferies 2014 Global Healthcare Conference
PR Newswire - Tue Nov 11, 3:00PM CST
Haemonetics Corporation (NYSE: HAE) announced today that Gerry Gould, Vice President, Investor Relations, will present at the Jefferies 2014 Global Healthcare Conference in London, England on November 20, 2014 at 8:40 am GMT.
HAE: 36.66 (-0.33)
Update: Haemonetics Needs A Sales Growth Infusion Following Q3 Sales Miss And EPS Beat
Martin Vlcek - at Seeking Alpha - Wed Nov 05, 8:56AM CST
HAE: 36.66 (-0.33)
NYSE stocks posting largest percentage decreases
AP - Tue Nov 04, 5:02PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on New York Stock Exchange at the close of trading:
TLM.TO: 5.04 (+0.78), HLF: 38.79 (-1.92), FRM: 7.34 (-0.13), TLM: 4.29 (+0.60), AKS: 5.20 (-0.13), CIE: 7.82 (+0.19), RCAP: 11.81 (-0.10), GDP: 3.93 (-0.33), LRE: 7.47 (-0.06), HAE: 36.66 (-0.33), S: 4.08 (-0.32), SGY: 13.64 (+0.08), BAS: 5.22 (+0.05), GVA: 35.74 (-0.48), HELI: 3.62 (-0.04), AP: 17.67 (-0.27), CRK: 5.26 (-0.49)
Haemonetics Q2 Earnings Beat Estimates but Decline Y/Y - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 12:20PM CST
Haemonetics Corporation (HAE) reported adjusted earnings of 47 cents per share in the second quarter of fiscal 2015.
BSX: 13.00 (+0.11), ICUI: 80.95 (-1.04), ABAX: 57.20 (+0.61), HAE: 36.66 (-0.33)
Haemonetics' (HAE) CEO Brian Concannon on Q2 2015 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Mon Nov 03, 10:42AM CST
HAE: 36.66 (-0.33)
Haemonetics affirms revenue and earnings guidance after FQ2 results
Seeking Alpha - at Seeking Alpha - Mon Nov 03, 6:54AM CST
HAE: 36.66 (-0.33)
Haemonetics beats 2Q profit forecasts
Automated Insights - Mon Nov 03, 5:18AM CST
BRAINTREE, Mass. (AP) _ Haemonetics Corp. (HAE) on Monday reported fiscal second-quarter earnings of $7.5 million.
HAE: 36.66 (-0.33)
Haemonetics beats by $0.01, misses on revenue
Seeking Alpha - at Seeking Alpha - Mon Nov 03, 5:02AM CST
HAE: 36.66 (-0.33)
Haemonetics Reports 2nd Quarter Fiscal 2015 Revenue of $228 Million and Adjusted EPS of $0.47; Reaffirms Revenue and Earnings Guidance
PR Newswire - Mon Nov 03, 5:00AM CST
Haemonetics Corporation (NYSE: HAE) today reported second quarter fiscal 2015 revenue of $227.6 million, down 3.5%. In constant currency, revenue declined 2.6% in the quarter. The Company reported second quarter GAAP net income of $7.5 million and GAAP net income per share of $0.14. Exclusive of transformation, restructuring and deal amortization expenses detailed below, adjusted net income was $24.3 million and adjusted earnings per share were $0.47, both down 29%.[1]
HAE: 36.66 (-0.33)
Notable earnings before Monday’s open
Seeking Alpha - at Seeking Alpha - Sun Nov 02, 4:30PM CST
ACW: 4.57 (-0.14), SYY: 39.33 (-0.80), L: 39.44 (-0.98), EEP: 38.31 (-0.94), SNH: 22.60 (+0.08), INN: 11.71 (-0.28), ITG: 19.60 (-0.21), NSP: 31.36 (-0.48), S: 4.08 (-0.32), ALE: 52.12 (-0.43), GVA: 35.74 (-0.48), MCY: 54.42 (-1.00), ARNA: 3.91 (-0.18), CHD: 76.00 (-0.80), ARE: 87.94 (-1.21), USAK: 22.52 (-0.24), BWP: 15.81 (+0.07), KRG: 27.78 (unch), CYOU: 23.01 (+0.40), MNKD: 5.11 (-0.14), HNT: 51.50 (-0.11), AMH: 16.89 (-0.22), ARCB: 44.00 (+0.21), ANIP: 54.28 (+2.33), AMG: 194.80 (-9.02), HAE: 36.66 (-0.33), SOHU: 47.82 (+0.37), CNA: 37.79 (-0.72)
Haemonetics reports November 3
Seeking Alpha - at Seeking Alpha - Sat Nov 01, 4:46PM CDT
HAE: 36.66 (-0.33)
Is Haemonetics (HAE) Poised to Beat on Q2 Earnings? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Oct 30, 5:15PM CDT
Haemonetics (HAE) has delivered positive earnings surprises in three of the past four quarters with an average beat of 1.9%
HAE: 36.66 (-0.33), HTWR: 70.66 (+0.18), HOLX: 25.85 (-0.52), HSP: 60.33 (-1.75)
3PEA International and Haemonetics Partner to Integrate PaySign Connect with Haemonetics' Donor Management System
Business Wire - Tue Oct 21, 7:49AM CDT
3PEA International, Inc. (OTCBB:TPNL)(OTCQB:TPNL), a vertically integrated provider of innovative prepaid card programs and processing services for corporate, consumer and government applications, today announced that 3PEA and Haemonetics Corporation (NYSE:HAE) have entered into an agreement whereby 3PEA International will integrate its PaySign(R) Connect prepaid debit card solution with Haemonetics' Donor Management System ("DMS"
. The integration will allow users of the Haemonetics DMS to use the PaySign Connect payment solution for the plasma industry. This partnership will bring together the best of both worlds, the industry leading Haemonetics Donor Management System and 3PEA's PaySign(R) Connect, an intuitive, easy-to-use, fully tokenized payment system tailored to the unique requirements of the plasma collection industry. HAE: 36.66 (-0.33)
Haemonetics Sets Date for Second Quarter Fiscal Year 2015 Earnings Release: November 3, 2014
PR Newswire - Mon Oct 06, 3:00PM CDT
Haemonetics Corporation (NYSE:HAE) will announce its earnings for the second quarter of its fiscal year 2015 on November 3, 2014 in a pre-market press release. The Company will host a webcast to discuss and answer questions about the press release at 8:00 am eastern time on November 3, 2014.
HAE: 36.66 (-0.33)
Perrigo Sells Some Assets to Imago Pharmaceuticals - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 03, 3:45PM CDT
Perrigo (PRGO) has out licensed some of its early-stage assets.
BIIB: 344.49 (+2.16), PRGO: 153.41 (-3.13), ABAX: 57.20 (+0.61), HAE: 36.66 (-0.33)
Walgreens Earnings in Line, Alliance Boots Shows Synergy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 30, 9:45AM CDT
Walgreen Co. (WAG) reported adjusted net earnings of 74 cents per share in the fourth quarter of fiscal 2014.
ABAX: 57.20 (+0.61), HAE: 36.66 (-0.33), CVS: 89.94 (-0.99), WAG: 74.50 (+1.49)
Data Intensity Fortifies Track Record of Success in Oracle EBS R12 Implementations and Upgrades
PR Newswire - Tue Sep 23, 8:30AM CDT
Data Intensity, the industry leader in managed and cloud services for Oracle technologies and applications, today announced a significant milestone in the company's rich history of driving implementations and upgrades to Oracle E-Business Suite (EBS) Release 12 (R12) for its global customers. Data Intensity is celebrating the inception of its dedicated application engineering team, established five years ago this month to address the market need for expertise in planning, managing and executing on the most complex Oracle projects. The team also recently completed one of its most challenging upgrades to date for Haemonetics Corp, a global healthcare company that provides innovative blood management solutions. This deployment was one of ten R12 projects Data Intensity has delivered successfully this year, and the most recent of the 70+ R12-focused engagements the team has completed since the technology's release in 2007.
HAE: 36.66 (-0.33)
Haemonetics (HAE) Poised on Strong Q2, Optimistic Outlook - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Sep 19, 5:00PM CDT
On Sep 19, 2014, we issued an updated research report on Haemonetics Corporation (HAE).
ICUI: 80.95 (-1.04), ABAX: 57.20 (+0.61), HAE: 36.66 (-0.33), HSP: 60.33 (-1.75)
